1. Home
  2. SANG vs CGEN Comparison

SANG vs CGEN Comparison

Compare SANG & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sangoma Technologies Corporation

SANG

Sangoma Technologies Corporation

HOLD

Current Price

$4.62

Market Cap

163.0M

Sector

Technology

ML Signal

HOLD

Logo Compugen Ltd.

CGEN

Compugen Ltd.

N/A

Current Price

$1.73

Market Cap

148.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SANG
CGEN
Founded
1984
1993
Country
Canada
Israel
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
163.0M
148.7M
IPO Year
2018
2001

Fundamental Metrics

Financial Performance
Metric
SANG
CGEN
Price
$4.62
$1.73
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
5.5K
203.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.07
$164.92
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.08
$1.13
52 Week High
$6.46
$2.38

Technical Indicators

Market Signals
Indicator
SANG
CGEN
Relative Strength Index (RSI) 43.95 44.73
Support Level $4.40 $1.47
Resistance Level $4.98 $1.72
Average True Range (ATR) 0.12 0.09
MACD -0.01 -0.01
Stochastic Oscillator 40.00 45.87

Price Performance

Historical Comparison
SANG
CGEN

About SANG Sangoma Technologies Corporation

Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Share on Social Networks: